NasdaqGS:PCVXBiotechs
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative
Vaxcyte recently reported in The Lancet Infectious Diseases that its 31-valent pneumococcal conjugate vaccine candidate VAX-31 showed strong immune responses and a safety profile similar to Prevnar 20 in a Phase 1/2 study of 1,015 adults aged 50 and older, and has since advanced the high-dose regimen into the OPUS Phase 3 adult program.
An important insight from these data is that VAX-31 met or exceeded regulatory immunogenicity criteria for all 31 serotypes at higher doses while covering...